SAN FRANCISCO: Genentech has hired Weber Shandwick to oversee all PR support for its cancer drug Rituxan.
The drug, which currently has FDA approval to treat non-Hodgkin's lymphoma, is undergoing clinical trials for rheumatoid arthritis.
Megan Pace, senior manager of product communications at Genentech, noted that this is the first time the company has worked with Weber Shandwick.
The agency won the account through a formal RFP. Pace declined to discuss the other firms that were considered.
She added that Genentech doesn't usually publicize agency projects and, therefore, wouldn't discuss the nature of the work.
Results from Phase IIa clinical trials with the drug were recently published in the New England Journal of Medicine.